MSEI Symbol				
Scrip code	524606			
NSE Symbol				
MSEI Symbol				
ISIN	INE415H01017			
Name of the entity	BERYL DRUGS LIMITED			
Date of start of financial year	01-04-2017			
Date of end of financial year	31-03-2018			
Reporting Quarter	Yearly			
Date of Report	31-03-2018			
Risk management committee	Not Applicable			

Annexure I	
Annexure I to be submitted by listed entity on quarterly basis	
I. Composition of Board of Directors	
Disclosure of notes on composition of board of directors explanatory	
Is there any change in information of board of directors compare to previous quarter	No

Annexure 1			
II. Composition of Committees			
Disclosure of notes on composition of committees explanatory			
Is there any change in information of committees compare to previous quarter	No		

Audit Committee Details					
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Remarks

Non	Nomination and remuneration committee					
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Remarks	

Stal	Stakeholders Relationship Committee					
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Remarks	

Risl	Risk Management Committee					
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Remarks	

Cor	Corporate Social Responsibility Committee				
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Remarks

Ot	her Committee					
Sr	DIN Number	Name of Committee members	Name of other committee	Category 1 of directors	Category 2 of directors	Remarks

	Annexure 1						
An	Annexure 1						
Ш	III. Meeting of Board of Directors						
Disclosure of notes on meeting of board of directors explanatory							
Sr	Date(s) of meeting (if any) in the previous quarter	Maximum gap between any two consecutive (in number of days)					
1	04-11-2017						
2		09-02-2018	96				

	Annexure 1							
IV.	IV. Meeting of Committees							
	Disclosure of notes on meeting of committees explanatory							
Sr	Name of Committee	Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (Yes/No)	Requirement of Quorum met	Date(s) of meeting of the committee in the previous quarter	Maximum gap between any two consecutive meetings (in number of days)	Name of other committee	
1	Audit Committee	09-02-2018	Yes	3	04-11-2017	96		
2	Stakeholders Relationship Committee	10-02-2018	Yes	3	03-11-2017	98		

	Annexure 1						
V.	V. Related Party Transactions						
Sr Subject Compliance status (Yes/No/NA) If status is "No" details of non-compliance may be given here.							
1	Whether prior approval of audit committee obtained	NA					
2	Whether shareholder approval obtained for material RPT	NA					
3	Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	NA					

	Annexure 1			
VI	Affirmations			
Sr	Subject	Compliance status (Yes/No)		
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes		
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes		
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes		
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes		
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 100 listed entities)	NA		
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes		
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes		
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes		

	Annexure 1		
Sr	Subject	Compliance status	
1	Name of signatory	SUDHIR SETHI	
2	Designation	Director	

	Annexure II					
	Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)					
I. I	I. Disclosure on website in terms of Listing Regulations					
Sr	Item	Compliance status (Yes/No/NA)	If status is "No" details of non- compliance may be given here.	Web address		
1	Details of business	Yes		www.beryldrugs.com		
2	Terms and conditions of appointment of independent directors	Yes		www.beryldrugs.com		
3	Composition of various committees of board of directors	Yes		www.beryldrugs.com		
4	Code of conduct of board of directors and senior management personnel	Yes		www.beryldrugs.com		
5	Details of establishment of vigil mechanism/ Whistle Blower policy	Yes		www.beryldrugs.com		
6	Criteria of making payments to non-executive directors	NA				
7	Policy on dealing with related party transactions	NA				
8	Policy for determining 'material' subsidiaries	NA				
9	Details of familiarization programmes imparted to independent directors	Yes		www.beryldrugs.com		

	Annexure II				
	Annexure II to be submitted by listed entity at the	end of the financ	ial year (for the whole of fina	ncial year)	
I. I	Disclosure on website in terms of Listing Regulations				
Sr	Item	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	Web address	
10	Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes		www.beryldrugs.com	
11	email address for grievance redressal and other relevant details	Yes		www.beryldrugs.com	
12	Financial results	Yes		www.beryldrugs.com	
13	Shareholding pattern	Yes		www.beryldrugs.com	
14	Details of agreements entered into with the media companies and/or their associates	Yes		www.beryldrugs.com	
15	New name and the old name of the listed entity	NA			

	Annexure II				
II.	Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non- compliance may be given here.	
1	Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility'	16(1)(b) & 25(6)	Yes		
2	Board composition	17(1)	Yes		
3	Meeting of Board of directors	17(2)	Yes		
4	Review of Compliance Reports	17(3)	Yes		
5	Plans for orderly succession for appointments	17(4)	NA		
6	Code of Conduct	17(5)	Yes		
7	Fees/compensation	17(6)	Yes		
8	Minimum Information	17(7)	Yes		
9	Compliance Certificate	17(8)	Yes		
10	Risk Assessment & Management	17(9)	Yes		

	Annexure II				
II.	Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non- compliance may be given here.	
11	Performance Evaluation of Independent Directors	17(10)	Yes		
12	Composition of Audit Committee	18(1)	Yes		
13	Meeting of Audit Committee	18(2)	Yes		
14	Composition of nomination & remuneration committee	19(1) & (2)	Yes		
15	Composition of Stakeholder Relationship Committee	20(1) & (2)	Yes		
16	Composition and role of risk management committee	21(1),(2),(3), (4)	NA		
17	Vigil Mechanism	22	Yes		
18	Policy for related party Transaction	23(1),(5),(6), (7) & (8)	NA		
19	Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	NA		
20	Approval for material related party transactions	23(4)	NA		

	Annexure II			
II.	Annual Affirmations			
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
21	Composition of Board of Directors of unlisted material Subsidiary	24(1)	NA	
22	Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3), (4),(5) & (6)	NA	
23	Maximum Directorship & Tenure	25(1) & (2)	Yes	
24	Meeting of independent directors	25(3) & (4)	Yes	
25	Familiarization of independent directors	25(7)	Yes	
26	Memberships in Committees	26(1)	Yes	
27	Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
28	Disclosure of Shareholding by Non-Executive Directors	26(4)	Yes	
29	Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	
	Any other information to be provided - Add Notes			

	Annexure II	
1	Name of signatory	
2	Designation	

	Annexure II		
Ш	III. Affirmations		
Sr	Particulars	Compliance status (Yes/No/NA)	
1	The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied	NA	
	Any other information to be provided		

Annexure II		[
1	Name of signatory	SUDHIR SETHI
2	Designation	Director

Signatory Details	
Name of signatory	SUDHIR SETHI
Designation of person	Director
Place	INDORE
Date	10-04-2018